Adrenergic beta-Antagonists
"Adrenergic beta-Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
| Descriptor ID |
D000319
|
| MeSH Number(s) |
D27.505.519.625.050.200.200 D27.505.696.577.050.200.200
|
| Concept/Terms |
Adrenergic beta-Antagonists- Adrenergic beta-Antagonists
- Adrenergic beta Antagonists
- beta-Antagonists, Adrenergic
- beta-Adrenergic Receptor Blockaders
- Blockaders, beta-Adrenergic Receptor
- Receptor Blockaders, beta-Adrenergic
- beta Adrenergic Receptor Blockaders
- beta-Adrenergic Blockers
- Blockers, beta-Adrenergic
- beta Adrenergic Blockers
- beta-Blockers, Adrenergic
- Adrenergic beta-Blockers
- beta Blockers, Adrenergic
- Adrenergic beta-Receptor Blockaders
- Adrenergic beta Receptor Blockaders
- Blockaders, Adrenergic beta-Receptor
- beta-Receptor Blockaders, Adrenergic
- beta-Adrenergic Blocking Agents
- Agents, beta-Adrenergic Blocking
- Blocking Agents, beta-Adrenergic
- beta Adrenergic Blocking Agents
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-Antagonists".
This graph shows the total number of publications written about "Adrenergic beta-Antagonists" by people in this website by year, and whether "Adrenergic beta-Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 |
| 1996 | 0 | 2 | 2 |
| 1997 | 5 | 2 | 7 |
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 3 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 2 | 3 | 5 |
| 2003 | 5 | 3 | 8 |
| 2004 | 2 | 2 | 4 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 7 | 8 |
| 2007 | 7 | 4 | 11 |
| 2008 | 4 | 4 | 8 |
| 2009 | 2 | 7 | 9 |
| 2010 | 2 | 4 | 6 |
| 2011 | 4 | 7 | 11 |
| 2012 | 4 | 2 | 6 |
| 2013 | 6 | 6 | 12 |
| 2014 | 9 | 4 | 13 |
| 2015 | 6 | 3 | 9 |
| 2016 | 5 | 4 | 9 |
| 2017 | 5 | 2 | 7 |
| 2018 | 6 | 3 | 9 |
| 2019 | 6 | 4 | 10 |
| 2020 | 3 | 3 | 6 |
| 2021 | 3 | 3 | 6 |
| 2022 | 1 | 4 | 5 |
| 2023 | 1 | 4 | 5 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic beta-Antagonists" by people in Profiles.
-
Use of Early Intravenous Beta Blockers in Patients with Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure-Revival or Requiem? Cardiovasc Drugs Ther. 2024 Oct; 38(5):973-975.
-
Protective Effects of ?-Blockers on Bone in Older Adults with Dementia. Calcif Tissue Int. 2024 Jul; 115(1):14-22.
-
How do we define high and low dose intensity of heart failure medications: a scoping review. BMC Cardiovasc Disord. 2023 09 27; 23(1):478.
-
Practice Variations in Managing Infantile Hemangiomas. J Pediatr Hematol Oncol. 2023 11 01; 45(8):452-460.
-
Mortality, Outcomes, Costs, and Use of?Medicines Following a First Heart?Failure?Hospitalization: EVOLUTION HF. JACC Heart Fail. 2023 10; 11(10):1320-1332.
-
The median doses of beta-blockers among older adults with heart failure with reduced ejection fraction. J Am Geriatr Soc. 2023 10; 71(10):3322-3325.
-
Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol. 2023 06; 7:e2200490.
-
Propranolol Modulates Cerebellar Circuit Activity and Reduces Tremor. Cells. 2022 Dec 01; 11(23).
-
Heart?Failure Drug Treatment-Inertia,?Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 01; 11(1):1-14.
-
Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc. 2022 09; 97(9):1734-1751.